SG11202010744YA - Antibodies with modulated glycan profiles - Google Patents
Antibodies with modulated glycan profilesInfo
- Publication number
- SG11202010744YA SG11202010744YA SG11202010744YA SG11202010744YA SG11202010744YA SG 11202010744Y A SG11202010744Y A SG 11202010744YA SG 11202010744Y A SG11202010744Y A SG 11202010744YA SG 11202010744Y A SG11202010744Y A SG 11202010744YA SG 11202010744Y A SG11202010744Y A SG 11202010744YA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- modulated
- glycan profiles
- glycan
- profiles
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862665045P | 2018-05-01 | 2018-05-01 | |
| PCT/US2019/029850 WO2019213043A1 (en) | 2018-05-01 | 2019-04-30 | Antibodies with modulated glycan profiles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010744YA true SG11202010744YA (en) | 2020-11-27 |
Family
ID=66542532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010744YA SG11202010744YA (en) | 2018-05-01 | 2019-04-30 | Antibodies with modulated glycan profiles |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210062156A1 (en) |
| EP (2) | EP4316519A3 (en) |
| JP (1) | JP2021521854A (en) |
| KR (1) | KR20210005689A (en) |
| CN (1) | CN112074537A (en) |
| AU (1) | AU2019263008A1 (en) |
| BR (1) | BR112020022166A2 (en) |
| CA (1) | CA3099163A1 (en) |
| CL (1) | CL2020002810A1 (en) |
| EA (1) | EA202092576A1 (en) |
| IL (2) | IL278211B1 (en) |
| MA (1) | MA52490A (en) |
| MX (1) | MX2020011614A (en) |
| SG (1) | SG11202010744YA (en) |
| TW (1) | TW202003574A (en) |
| WO (1) | WO2019213043A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024006236A1 (en) * | 2022-06-28 | 2024-01-04 | Amgen Inc. | Flexible facility configurations for therapeutic product manufacturing |
| CN117825686A (en) * | 2024-03-05 | 2024-04-05 | 军科正源（北京）药物研究有限责任公司 | Sample pretreatment method for detecting denominator drug-resistant antibody and application thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US159259A (en) * | 1875-02-02 | Improvement in reservoir cooking-stoves | ||
| US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
| US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
| US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
| US7846724B2 (en) * | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| US9695244B2 (en) * | 2012-06-01 | 2017-07-04 | Momenta Pharmaceuticals, Inc. | Methods related to denosumab |
| TWI771890B (en) * | 2013-03-14 | 2022-07-21 | 美商安美基公司 | Methods for increasing mannose content of recombinant proteins |
| US8956830B2 (en) * | 2013-03-14 | 2015-02-17 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| JP6668241B2 (en) * | 2013-09-05 | 2020-03-18 | アムジエン・インコーポレーテツド | Fc-containing molecules exhibit predictable, consistent and reproducible glycoform properties |
-
2019
- 2019-04-30 CA CA3099163A patent/CA3099163A1/en active Pending
- 2019-04-30 KR KR1020207033991A patent/KR20210005689A/en not_active Application Discontinuation
- 2019-04-30 EP EP23200813.6A patent/EP4316519A3/en active Pending
- 2019-04-30 CN CN201980029448.7A patent/CN112074537A/en active Pending
- 2019-04-30 MX MX2020011614A patent/MX2020011614A/en unknown
- 2019-04-30 WO PCT/US2019/029850 patent/WO2019213043A1/en unknown
- 2019-04-30 IL IL278211A patent/IL278211B1/en unknown
- 2019-04-30 EA EA202092576A patent/EA202092576A1/en unknown
- 2019-04-30 SG SG11202010744YA patent/SG11202010744YA/en unknown
- 2019-04-30 MA MA052490A patent/MA52490A/en unknown
- 2019-04-30 US US17/051,528 patent/US20210062156A1/en active Pending
- 2019-04-30 AU AU2019263008A patent/AU2019263008A1/en active Pending
- 2019-04-30 BR BR112020022166-0A patent/BR112020022166A2/en unknown
- 2019-04-30 EP EP19724307.4A patent/EP3788076A1/en active Pending
- 2019-04-30 IL IL307155A patent/IL307155A/en unknown
- 2019-04-30 JP JP2020560390A patent/JP2021521854A/en active Pending
- 2019-05-01 TW TW108115162A patent/TW202003574A/en unknown
-
2020
- 2020-10-29 CL CL2020002810A patent/CL2020002810A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL278211B1 (en) | 2023-10-01 |
| CN112074537A (en) | 2020-12-11 |
| IL307155A (en) | 2023-11-01 |
| MA52490A (en) | 2021-03-10 |
| EP4316519A3 (en) | 2024-04-24 |
| US20210062156A1 (en) | 2021-03-04 |
| TW202003574A (en) | 2020-01-16 |
| AU2019263008A1 (en) | 2020-11-19 |
| WO2019213043A1 (en) | 2019-11-07 |
| CA3099163A1 (en) | 2019-11-07 |
| MX2020011614A (en) | 2020-12-09 |
| IL278211A (en) | 2020-11-30 |
| BR112020022166A2 (en) | 2021-01-26 |
| EP3788076A1 (en) | 2021-03-10 |
| JP2021521854A (en) | 2021-08-30 |
| CL2020002810A1 (en) | 2021-02-19 |
| KR20210005689A (en) | 2021-01-14 |
| EA202092576A1 (en) | 2021-02-05 |
| EP4316519A2 (en) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279321A (en) | Anti-sirpα antibody | |
| EP3589313A4 (en) | Anti-tigit antibodies | |
| IL280780A (en) | Anti-tigit antibodies | |
| IL279352A (en) | Il-11ra antibodies | |
| EP3569709A4 (en) | Anti-gpc3 antibody | |
| IL280013A (en) | Anti-il36r antibodies | |
| IL278010A (en) | Galectin-10 antibodies | |
| EP3661558A4 (en) | Anti-il1rap antibodies | |
| EP3606961B8 (en) | Garp-tgf-beta antibodies | |
| EP3684806A4 (en) | Novel anti-cd3epsilon antibodies | |
| EP3691447A4 (en) | Anti-transthyretin antibodies | |
| IL277030A (en) | Antibodies | |
| SG11202106171WA (en) | Anti-btla antibodies | |
| EP3596126A4 (en) | Novel anti-trkb antibodies | |
| ZA202101177B (en) | Anti-btla antibody | |
| GB201811368D0 (en) | Antibody | |
| AU2019361253A1 (en) | Anti-synuclein antibodies | |
| GB201811403D0 (en) | Antibody molecules | |
| IL281594A (en) | Anti-klrg1 antibodies | |
| GB201817172D0 (en) | Antibody | |
| EP3579879A4 (en) | Anti-kir3dl1 antibodies | |
| IL278211A (en) | Antibodies with modulated glycan profiles | |
| GB201806084D0 (en) | Antibodies | |
| EP3720492A4 (en) | Anti-rspo3 antibodies | |
| SG11202105718TA (en) | Modified antibodies |